Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Terminated Phase 2 Interventional Results available

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

NCT03946670
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
MBG453, Placebo, Hypomethylating agents
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Dexamethasone in Controlling Dyspnea in Patients With Cancer

NCT03367156
View directory record Official record
Conditions
Dyspnea, Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Study of Food Aversion in Patients With Anorexia Nervosa

NCT03100656
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
A breakfast sandwich
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 30, 2026, 9:23 AM EDT
Suspended Phase 1Phase 2 Interventional

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

NCT05643729
View directory record Official record
Conditions
COPD
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BI 3000202, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Beverly Hills, California • La Palma, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

NCT02036528
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
Drug
Lead sponsor
Royer Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional

Zenapax to Treat Multiple Sclerosis

NCT00001934
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Zenapax
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 30, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)

NCT07450209
View directory record Official record
Conditions
COVID-19 Testing Behaviors
Interventions
COVID-19 rapid test-to-treat, Standard COVID19 education control arm
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 120 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

NCT01552681
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
Baminercept, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 30, 2026, 9:23 AM EDT
Enrolling by invitation No phase listed Observational

Health eHeart BEAT-AFib - Health eHeart Biomarkers of Early Atrial Transformation in Atrial Fibrillation

NCT04404465
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

NCT04374630
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Paclitaxel, Afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Rogers, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

NCT03393975
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755, Standard of care
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
0 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
View directory record Official record
Conditions
Prehypertension, Hypertension, Stage I
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Music in Reducing Distress in Participants with Cancer During Chemotherapy Treatment

NCT03683420
View directory record Official record
Conditions
Caregiver, Malignant Neoplasm
Interventions
Music Therapy
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

NCT01360840
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
EMD 525797, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 30, 2026, 9:23 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

The Medically Reproducing Bariatric Surgery (MRB) II Study

NCT06363747
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Very Low Calorie Diet
Other
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
25 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 9:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

NCT04530955
View directory record Official record
Conditions
Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions
Prometra II Programmable Pump - Flowonix Medical
Device
Lead sponsor
Culicchia Neurological Clinic
Other
Eligibility
22 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marrero, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880399
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
orvepitant, placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 30, 2026, 9:23 AM EDT